Epigenomics and interindividual differences in drug response

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 6, 2012, Pages 727-736

  Ivanov, M ^a   Kacevska, M ^a   Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; ANTHRACYCLINE; AZACITIDINE; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CALCITRIOL; CISPLATIN; CURCUMIN; CYTOCHROME P450 1B1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DOXORUBICIN; EPZ 004777; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; METHOTREXATE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; NUCLEIC ACID; OLAPARIB; PACLITAXEL; RNA; ROMIDEPSIN; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ARTICLE; BODY FLUID; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; COLORECTAL TUMOR; DNA METHYLATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; T CELL LEUKEMIA; TREATMENT RESPONSE;

ANIMALS; BODY FLUIDS; DNA METHYLATION; DRUG RESISTANCE; ENZYMES; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; NUCLEIC ACIDS; OPEN READING FRAMES; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; RNA;

EID: 84869500199     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.152     Document Type: Article

References (74)

1. Sim, S.C. & Ingelman-Sundberg, M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol. Sci. 32, 72-81 (2011).
2. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
3. Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766-770 (2008).
4. Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295-304 (2009).
5. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874 (2011).
6. Iorio, M.V., Piovan, C. & Croce, C.M. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim. Biophys. Acta 1799, 694-701 (2010).
7. Münzel, M., Globisch, D. & Carell, T. 5-Hydroxymethylcytosine, the sixth base of the genome. Angew. Chem. Int. Ed. Engl. 50, 6460-6468 (2011).
8. Yildirim, O. et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147, 1498-1510 (2011).
9. Xu, Y. et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 42, 451-464 (2011).
10. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343-348 (2011).
11. Szulwach, K.E. et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14, 1607-1616 (2011).
12. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843 (2010).
13. Koh, K.P. et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 8, 200-213 (2011).
14. Tsai, M.C. et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689-693 (2010).
15. Gupta, R.A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076 (2010).
16. Aguilo, F., Zhou, M.M. & Walsh, M.J. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. 71, 5365-5369 (2011).
17. Pasmant, E., Sabbagh, A., Vidaud, M. & Bièche, I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 25, 444-448 (2011).
18. Pontier, D.B. & Gribnau, J. Xist regulation and function explored. Hum. Genet. 130, 223-236 (2011).
19. Kuramochi-Miyagawa, S. et al. DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine fetal testes. Genes Dev. 22, 908-917 (2008). (Pubitemid 351482844)
20. Hawkins, P.G., Santoso, S., Adams, C., Anest, V. & Morris, K.V. Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Res. 37, 2984-2995 (2009).
21. Kacevska, M., Ivanov, M. & Ingelman-Sundberg, M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin. Pharmacol. Ther. 89, 902-907 (2011).
22. Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413 (2002). (Pubitemid 34983477)
23. Hong, S.J. et al. DNA methylation patterns of ulcer-healing genes associated with the normal gastric mucosa of gastric cancers. J. Korean Med. Sci. 25, 405-417 (2010).
24. Tobi, E.W. et al. DNA methylation differences after exposure to prenatal famine are common and timing-and sex-specific. Hum. Mol. Genet. 18, 4046-4053 (2009).
25. Baker, E.K., Johnstone, R.W., Zalcberg, J.R. & El-Osta, A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24, 8061-8075 (2005). (Pubitemid 41746749)
26. Tekpli, X., Zienolddiny, S., Skaug, V., Stangeland, L., Haugen, A. & Mollerup, S. DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int. J. Cancer 131, 1509-1516 (2012).
27. Kaut, O., Schmitt, I. & Wüllner, U. Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 13, 87-91 (2012).
28. Wu, Y. et al. Histone deacetylase 1 is required for Carbamazepine-induced CYP3A4 expression. J. Pharm. Biomed. Anal. 58, 78-82 (2012).
29. Agrelo, R. et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. USA 103, 8822-8827 (2006). (Pubitemid 43878103)
30. Rukov, J.L. & Shomron, N. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol. Med. 17, 412-423 (2011).
31. Nasser, M.W. et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 283, 33394-33405 (2008).
32. Giovannetti, E. et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528-4538 (2010).
33. Hwang, J.H. et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5, e10630 (2010).
34. Hung, E.C., Chiu, R.W. & Lo, Y.M. Detection of circulating fetal nucleic acids: a review of methods and applications. J. Clin. Pathol. 62, 308-313 (2009).
35. Boddy, J.L., Gal, S., Malone, P.R., Harris, A.L. & Wainscoat, J.S. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin. Cancer Res. 11, 1394-1399 (2005). (Pubitemid 40315218)
36. Urbanova, M., Plzak, J., Strnad, H. & Betka, J. Circulating nucleic acids as a new diagnostic tool. Cell. Mol. Biol. Lett. 15, 242-259 (2010).
37. Kim, G.E. et al. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients. Virchows Arch. 459, 383-390 (2011).
38. Begum, S. et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17, 4494-4503 (2011).
39. Cortese, R. et al. Epigenetic markers of prostate cancer in plasma circulating DNA. Hum. Mol. Genet. 21, 3619-3631 (2012).
40. Lin, Y.L., Sun, G., Liu, X.Q., Li, W.P. & Ma, J.G. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J. Int. Med. Res. 39, 179-186 (2011).
41. Hibi, K. et al. Detection of TFPI2 methylation in the serum of colorectal cancer patients. Cancer Lett. 311, 96-100 (2011).
42. Liggett, T.E., Melnikov, A.A., Marks, J.R. & Levenson, V.V. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int. J. Cancer 128, 492-499 (2011).
43. Avraham, A. et al. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int. J. Cancer 131, E1166-E1172 (2012).
44. C ortez, M.A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A.K. & Calin, G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8, 467-477 (2011).
45. Fojo, T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updat. 10, 59-67 (2007). (Pubitemid 46656478)
46. Glasspool, R.M., Teodoridis, J.M. & Brown, R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 94, 1087-1092 (2006).
47. Liu, F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan. J. Obstet. Gynecol. 48, 239-244 (2009).
48. Bram, E.E., Stark, M., Raz, S. & Assaraf, Y.G. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11, 1359-1370 (2009).
49. Hauswald, S. et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 15, 3705-3715 (2009).
50. El-Khoury, V., Breuzard, G., Fourré, N. & Dufer, J. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br. J. Cancer 97, 562-573 (2007). (Pubitemid 47258462)
51. Zeller, C. et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene (2012); e-pub ahead of print 16 January 2012.
52. Chen, H.Y., Shao, C.J., Chen, F.R., Kwan, A.L. & Chen, Z.P. Role of ERCC 1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 126, 1944-1954 (2010).
53. Wang, Q., Zhong, M., Liu, W., Li, J., Huang, J. & Zheng, L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp. Lung Res. 37, 427-434 (2011).
54. Zhu, W. et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med. Oncol. 29, 384-391 (2012).
55. Pathiraja, T.N., Stearns, V. & Oesterreich, S. Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response. J. Mammary Gland Biol. Neoplasia 15, 35-47 (2010).
56. Widschwendter, M. et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64, 3807-3813 (2004). (Pubitemid 38697289)
57. Fiegl, H. et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65, 1141-1145 (2005). (Pubitemid 40270136)
58. Iorns, E. et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91-104 (2008). (Pubitemid 351163160)
59. Chang, X. et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 70, 2870-2879 (2010).
60. Yu, W. et al. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS ONE 6, e29450 (2011).
61. Yamamoto, Y. et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol. Cancer 10, 135 (2011).
62. Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
63. Marmorstein, R. & Trievel, R.C. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim. Biophys. Acta 1789, 58-68 (2009).
64. Song, S.H., Han, S.W. & Bang, Y.J. Epigenetic-based therapies in cancer: progress to date. Drugs 71, 2391-2403 (2011).
65. Chang, Y. et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol. 400, 1-7 (2010).
66. Daigle, S.R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
67. Lohse, B. et al. Inhibitors of histone demethylases. Bioorg. Med. Chem. 19, 3625-3636 (2011).
68. Dekker, F.J. & Haisma, H.J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 14, 942-948 (2009).
69. Unoki, M., Brunet, J. & Mousli, M. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem. Pharmacol. 78, 1279-1288 (2009).
70. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010).
71. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
72. Mertz, J.A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108, 16669-16674 (2011).
73. Choi, S.H., Heo, K., Byun, H.M., An, W., Lu, W. & Yang, A.S. Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res. 39, 104-118 (2011).
74. Amato, R.J. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin. Genitourin. Cancer 5, 422-426 (2007). (Pubitemid 351219694)